TABLE 2.
Acamprosate (n = 12) | Placebo (n = 11) | Significance (Acamprosate vs Placebo) | |
---|---|---|---|
HAM-D-17 at baseline, mean ± SD | 15.6 ± 5.2 | 20.7 ± 5.8 | P = 0.036* Mann-Whitney: U = 33.00, Z = −2.03, P = 0.042* |
HAM-D-17 at end point, mean ± SD | 10.0 ± 7.2 | 12.9 ± 9.8 | t = −0.814, df = 21, P = 0.425 |
Change in HAM-D-17 score, mean ± SD | −5.6 ± 8.5 | −7.8 ± 9.9 | t = 0.579, df = 21, P = 0.566 |
Significance for change in HAM-D-17 score | t = 2.28, P = 0.043* Wilcoxon: Z = −2.05, P = 0.041*) | t = 2.62, P = 0.026* Wilcoxon: Z = − 2.14, P = 0.033* | NA |
QIDS-SR at baseline, mean ± SD | 10.7 ± 3.5 | 13.2 ± 3.7 | t = −1.667, df = 21, P = 0.110 |
QIDS-SR at end point, mean ± SD | 7.5 ± 5.1 | 9.4 ± 6.2 | t = −0.788, df = 21, P = 0.439 |
Change in QIDS-SR, mean ± SD | −3.2 ± 5.0 | −3.8 ± 5.2 | t = 0.308, df = 21, P = 0.761 |
Significance for change in QIDS-SR score | t = 2.22, P = 0.049* Wilcoxon: Z = −2.05, P = 0.040* | t = 2.44, P = 0.035* Wilcoxon: Z = −2.11, P = 0.035* | NA |
CGI-S at baseline, mean ± SD | 3.3 ± 0.8 | 4.4 ± 0.7 | t = −3.378, df = 21, P = 0.003* Mann Whitney: U = 23.00, Z = −2.83, P = 0.005* |
CGI-S at end point, mean ± SD | 2.6 ± 1.2 | 3.0 ± 1.6 | t = −0.705, df = 18, P = 0.490 |
Change in CGI-S, mean ± SD | −0.75 ± 1.4 | −1.4 ± 1.7 | t = 0.945, df = 21, P = 0.355 |
Significance for change in CGI-S score | t = 1.92, P = 0.082 Wilcoxon: Z = −1.64, P = 0.101 | t = 2.59, P = 0.027* Wilcoxon: Z = −2.04, P = 0.041* | NA |
CGI-I at end point, mean ± SD | 2.8 ± 1.2 | 2.9 ± 1.5 | t = −0.279, df = 21, P = 0.482 |
Response rate | 50% | 36% | χ2 = 0.43, P = 0.68 |
Remission rate | 42% | 36% | χ2 = 0.07, P = 1.00 |
Completers | 7 | 5 | χ2 = 0.38, P = 0.68 |
Statistically significant (P < 0.05).